Cadrenal Therapeutics, Inc.

CVKD · Nasdaq · SIC 2834: Pharmaceutical Preparations
84
SEC Filings

Business Summary

. The Company We are a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. As a result of our acquisition of a 12-lipoxygenase (12-LOX) platform of assets in December 2025 (as described in more detail below), we transitioned our primary strategic focus to the development of CAD-1005 for the treatment of immune-mediated and thrombotic disorders. Our lead product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor be...

Next Earnings

Q2 FY2026 — expected 2026-09-14

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionCVKDdiscussed_in_filing Artificial Intelligence
topic_mentionCVKDdiscussed_in_filing Cybersecurity
topic_mentionCVKDdiscussed_in_filing Trusted Computing
topic_mentionCVKDdiscussed_in_filing Blockchain & Crypto
topic_mentionCVKDdiscussed_in_filing Supply Chain
topic_mentionCVKDdiscussed_in_filing Regulation
topic_mentionCVKDdiscussed_in_filing Enterprise
topic_mentionCVKDdiscussed_in_filing Healthcare & Bio
topic_mentionCVKDdiscussed_in_filing Platform & Ecosystem
topic_mentionCVKDdiscussed_in_filing Sovereign & Government
topic_mentionCVKDdiscussed_in_filing Artificial Intelligence
topic_mentionCVKDdiscussed_in_filing Cybersecurity
topic_mentionCVKDdiscussed_in_filing Trusted Computing
topic_mentionCVKDdiscussed_in_filing Blockchain & Crypto
topic_mentionCVKDdiscussed_in_filing Supply Chain
topic_mentionCVKDdiscussed_in_filing Regulation
topic_mentionCVKDdiscussed_in_filing Enterprise
topic_mentionCVKDdiscussed_in_filing Healthcare & Bio
topic_mentionCVKDdiscussed_in_filing Platform & Ecosystem
topic_mentionCVKDdiscussed_in_filing Sovereign & Government

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-312025-12-310001213900-26-036946EDGAR85K words
2025-03-132024-12-310001213900-25-023759EDGAR—
2024-03-112023-12-310001213900-24-021133EDGAR—
2023-03-302022-12-310001213900-23-024260EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-102025-09-300001213900-25-107816EDGAR20K words
2025-08-112025-06-300001213900-25-073885EDGAR—
2025-05-082025-03-310001213900-25-040788EDGAR—
2024-11-072024-09-300001213900-24-095393EDGAR—
2024-08-072024-06-300001213900-24-066107EDGAR—
2024-05-092024-03-310001213900-24-041014EDGAR—
2023-11-092023-09-300001213900-23-084937EDGAR—
2023-08-102023-06-300001213900-23-065223EDGAR—
2023-05-102023-03-310001213900-23-037929EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-04-010001213900-26-038014EDGAR11K words
2026-03-310001213900-26-036937EDGAR—
2026-03-120001213900-26-026646EDGAR—
2026-02-240001213900-26-019606EDGAR—
2025-12-230001213900-25-125433EDGAR—
2025-12-160001213900-25-121932EDGAR—
2025-12-110001213900-25-120360EDGAR—
2025-12-010001213900-25-116307EDGAR—
2025-11-180001213900-25-112123EDGAR—
2025-11-100001213900-25-107949EDGAR—

84 total filings indexed. 61 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Company Identity

CIK0001937993
TickerCVKD
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 991383be30f81879f72b4eab80c2c1dca37ac2359a161cd3720feb98289680c6
parent: 4149834ae55d979e1a95d07d5c786436dab496614eaabb48f5d6b116dd2d037b
content hash: 497cffbc5d1a3c6c1c9f47476f81bd5b9701326e8cddc46c0a81ce82c3200329
signed: 2026-04-13T04:44:34.150Z
sources: 13 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf